Related Experiment Video
Updated: Dec 14, 2025
05:44
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
Published on: June 10, 2025
668
Biologics in Dermatology: Off-Label Indications
Debdeep Mitra1, Ajay Chopra1, Neerja Saraswat1
1Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India.
Indian Dermatology Online Journal
|July 23, 2020
Summary
Biologic therapies offer targeted treatments for skin diseases, especially for patients unresponsive to traditional therapies. This review explores the growing evidence for using biologics in dermatology for off-label indications.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Skin and subcutaneous diseases cause significant global morbidity.
- Biologics are emerging as crucial treatments for various skin conditions.
- They serve as alternatives for patients with inadequate responses or intolerance to conventional systemic therapies.
Purpose of the Study:
- To review the expanding evidence for biologic therapies in dermatology.
- To highlight the off-label applications of biologics in treating skin diseases.
Main Methods:
- Review of current scientific literature on biologic therapies in dermatology.
- Analysis of evidence supporting the efficacy and safety of biologics for immune-mediated skin diseases.
Main Results:
- Biologic therapies provide targeted treatment by interacting with specific immune and inflammatory pathways.
- Advances in understanding disease pathophysiology and drug development have accelerated the use of biologics.
- There is increasing evidence supporting the use of biologics for off-label dermatological conditions.
Conclusions:
- Biologics represent a significant advancement in managing inflammatory skin diseases.
- Their targeted mechanisms offer new therapeutic avenues for complex dermatological conditions.
- Further research and clinical application of biologics in dermatology are warranted, particularly for off-label uses.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
352
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
352
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
366
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
366
01:29Inflammatory Bowel Disease IV: Pharmacological Management
342
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
342
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
330
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
330
01:28Drug Products: Biologics, Biosimilars and Interchangeables
151
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
151
01:23Skin Diseases and Disorders
5.0K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.0K